Dan Zandberg
Clinical trials sponsored by Dan Zandberg, explained in plain language.
-
Tailored immunotherapy shows promise for tough head and neck cancers
Disease control CompletedThis study tested a personalized approach for people with advanced head and neck cancer that had already gotten worse after standard immunotherapy. Researchers used genetic testing of the tumor to choose which combination of immunotherapy drugs might work best for each person. Th…
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Triple threat: HPV vaccine plus immunotherapy shows promise against head and neck cancer
Disease control CompletedThis study tested a new treatment for a type of head and neck cancer linked to HPV-16. The treatment combined an HPV vaccine (ISA101b), an immunotherapy drug (pembrolizumab), and standard chemo-radiation. The goal was to see if this mix could help control the cancer for longer. T…
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
Cancer patients may not need lifelong immunotherapy, study suggests
Knowledge-focused CompletedThis study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…
Phase: PHASE3 • Sponsor: Dan Zandberg • Aim: Knowledge-focused
Last updated Jun 17, 2026 03:13 UTC